Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,800 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 9 Sepember 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 4MB, 239 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Author is Hallas, J.  [Clear All Filters]
Journal Article
V. Hoffman, Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., Phiri, K., Enger, C., Horter, L., Odsbu, I., Olesen, M., Perez-Gutthann, S., Xu, Y., Kristiansen, N. S., Appenteng, K., de Vogel, S., and Seeger, J. D., Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study, Drug Saf, vol. 44, pp. 899-915, 2021.
J. Castellsague, Kuiper, J. G., Pottegard, A., I. Berglind, A., Dedman, D., Gutierrez, L., Calingaert, B., van Herk-Sukel, M. P., Hallas, J., Sundstrom, A., Gallagher, A. M., Kaye, J. A., Pardo, C., Rothman, K. J., and Perez-Gutthann, S., A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study), Clin Epidemiol, vol. 10, pp. 299-310, 2018.
D. Gaist, Rodriguez, L. A., Huerta, C., Hallas, J., and Sindrup, S. H., Lipid-lowering drugs and risk of myopathy: a population-based follow-up study, Epidemiology, vol. 12, pp. 565-9, 2001.
A. V. Margulis, Linder, M., Arana, A., Pottegard, A., Berglind, I. A., Bui, C. L., Kristiansen, N. S., Bahmanyar, S., McQuay, L. J., Atsma, W. J., Appenteng, K., D'Silva, M., Perez-Gutthann, S., and Hallas, J., Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom, PLoS One, vol. 13, p. e0204456, 2018.
K. Phiri, Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., Bahmanyar, S., Hoffman, V., Enger, C., Horter, L., Odsbu, I., Olesen, M., Perez-Gutthann, S., Kristiansen, N. S., Appenteng, K., de Vogel, S., and Seeger, J., A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder, Curr Med Res Opin, p. 1, 2021.
J. G. Kuiper, van Herk-Sukel, M. P. P., Castellsague, J., Pottegard, A., Berglind, I. A., Dedman, D., Gutierrez, L., Calingaert, B., Hallas, J., Sundstrom, A., Gallagher, A. M., Kaye, J. A., Pardo, C., Rothman, K. J., and Perez-Gutthann, S., Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study, Drugs Real World Outcomes, 2018.
[Page last reviewed 9 September 2021]